# US 2013/0252992 A1 · Cyclic n,n'-diarylthiourea - androgen receptor antagonist, anti breast cancer composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252992 A1
- Document ID: US20130252992A1
- Status: Published application
- Kind: A1
- Application number: 13/831,929
- Filed: 2013-03-15
- Published: 2013-09-26
- Earliest claimed: 2010-07-22
- Inventors: Alexandre Vasilievich IVACHTCHENKO; Oleg Dmitrievich MITKIN
- Web page: https://patentgrep.com/patent/US20130252992A1

## CPC

- C07D 233/86: Oxygen and sulfur atoms, e.g. thiohydantoin
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel cyclic N,N′-diarylurea-androgen receptor antagonist, anti-cancer agent, pharmaceutical composition, medicament, and method for treatment of breast cancer disease. Cyclic N,N′-diarylthioureas or N,N′-diarylureas of the general formula 1, their optical (R)- and (S)-isomers and pharmaceutically acceptable salts thereof exhibiting properties of androgen receptor antagonists have been proposed, wherein: R1 represents C1-C3 alkyl; R4 and R5 represent hydrogen; or R4 represents hydrogen, R5 represents methyl; or R4 represents methyl, R5 represents CH2R6 group in which R6 is C1-C3 alkoxycarbonyl, carboxyl, hydroxyl group optionally substituted with methyl or benzyl; or R4 and R5 together with the carbon atom they are attached to form 5- or 6-membered saturated heterocycle including at least one oxygen atom or nitrogen atom optionally substituted with methyl.

## Claims

### Claim 1

A pharmaceutical composition for treating breast cancer comprising an effective amount of at least one cyclic N,N′-diarylthiourea compound of general formula 1.2, or an optical (R)- or (S)-isomer, or a pharmaceutically acceptable salt thereof, and further comprising a pharmaceutically acceptable carrier or an excipient,
wherein:
R1 represents C1-C3 alkyl;
R4 and R5 represent hydrogen; or
R4 represents hydrogen, R5 represents methyl; or
R4 represents methyl, R5 represents CH2R6 group in which R6 is C1-C3 alkoxycarbonyl, carboxyl, hydroxyl group optionally substituted with methyl or benzyl; or
R4 and R5 together with the carbon atom they are attached to form 5- or 6-membered saturated heterocycle including at least one oxygen atom or nitrogen atom optionally substituted with methyl.

### Claim 2 (depends on 1)

The composition of claim 1, wherein a compound selected from the group consisting of cyclic N,N′-diarylthioureas of formulas 1.2(1), 1.2 (2), 1.2.2, 1.2.3, optical (R)-isomers (R)-1.2(2), (R)-1.2.2, (R)-1.2.3, optical (S)-isomers (S)-1.2(2), (S)-1.2.2, and (S)-1.2.3, or a pharmaceutically acceptable salt thereof,

### Claim 3 (depends on 2)

The composition of claim 2, wherein a compound selected from the group consisting of compounds of formulas 1.2.2(1), 1.2.2(2), 1.2.2(3), 1.2.3(1), 1.2.3(2), 1.2.3(3), optical (R)-isomers (R)-1.2.2(1), (R)-1.2.2(2), (R)-1.2.2(3), (R)-1.2.3(1), optical (S)-isomers (S)-1.2.2(1), (S)-1.2.2(2), (S)-1.2.2(3), and (S)-1.2.3(1), or a pharmaceutically acceptable salt thereof,

### Claim 4 (depends on 1)

The composition of claim 1 in the form of a tablet, a capsule, or an injection placed in a pharmaceutically acceptable package.

### Claim 5 (depends on 1)

A method for treating a breast cancer in a subject comprising administering an effective dose of a pharmaceutical composition according to claim 1 to a subject in need thereof.
